Same Molecule, Different Road: How a Logistics Company Took On Novartis in the Radioligand Race | Plus Lilly's Breast Cancer Moat & Europe's Regulatory Wave

Three stories dominated oncology this week — and each one redefines what it takes to win. First, Eli Lilly's FDA approval of imlunestrant locks down ESR1-mutated breast cancer with a clinical moat that AstraZeneca's failed SERENA-4 trial couldn't crack, while Roche pivots to a tolerability play in early-stage disease. Then, Curium's Bexlutry shatters Novartis's radioligand monopoly using the exact same molecule, proving that in the age of decaying isotopes, logistics can trump R&D. Finally, five CHMP recommendations out of Europe reshape the competitive map — from Enhertu's leap into curative-intent adjuvant therapy to a Keytruda–Padcev combination that slams the door on bladder cancer competitors. Plus a lightning round covering Amgen access wins, GSK's $750M myeloma deal, and a wave of stealth trial registrations signaling a defensive land grab across lung and breast cancer.
Disclaimer: AI-generated from publicly available news. Not medical or investment advice. May contain errors — verify against primary sources.

(00:00) Introduction & What's Ahead This Week
(00:52) Lilly's Imlunestrant: FDA Approval & the ESR1 Mutation
(01:38) How Tumors Outsmart Hormone Therapy
(02:30) SERDs: A New Mechanism of Action
(02:53) EMBER-3 Trial Results — Doubling Progression-Free Survival
(03:38) AstraZeneca's SERENA-4 Failure & Lilly's Clinical Moat
(04:46) Roche's Strategic Pivot to Early-Stage Breast Cancer
(05:59) Curium's Bexlutry vs. Novartis's Lutathera
(06:30) How Radioligand Therapies Work
(07:17) The 505(b)(2) Pathway — Regulatory Shortcut or Disruption?
(08:32) The Supply Chain Battle — Decaying Isotopes & Logistics
(10:21) What Bexlutry Means for Radiopharmaceutical Investment
(11:03) Europe's Regulatory Wave — Five CHMP Recommendations
(11:49) Enhertu's Leap from Palliative to Curative Intent
(13:52) PARP Inhibitor Commoditization vs. Market Lock-Out
(15:29) Keytruda + Padcev Corner the Bladder Cancer Market
(16:13) Lightning Round — Five Headlines in Five Minutes
(17:43) Closing: The Evolving Definition of a Commercial Moat